Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis

Jianglong Han; Zhihua Nie; Ping Li; Hongwei Shi; Shijie Wang; Qin Li; Rui Zhang; Yunfeng Qiao; Kejie Huang; Zhenming Fu

doi:10.7150/jca.41082

Comparison of Treatment Modalities for Locally Advanced Gastric Cancer: A Propensity Score Matching Analysis

J Cancer. 2020 May 18;11(15):4421-4430. doi: 10.7150/jca.41082. eCollection 2020.

Authors

Jianglong Han¹, Zhihua Nie^{2

3}, Ping Li^{1

2}, Hongwei Shi¹, Shijie Wang¹, Qin Li¹, Rui Zhang¹, Yunfeng Qiao¹, Kejie Huang¹, Zhenming Fu¹

Affiliations

¹ Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
² Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
³ Taikang Tongji (Wuhan) Hospital, Wuhan, 430050, China.

Abstract

Background: A consensus regarding optimum treatment strategies for locally advanced gastric cancer (LAGC) has not yet been reached. We aimed to evaluate the efficacy of various treatment modalities for LAGC and provided clinicians salvage options under real-world situation. Methods: Medical charts of patients with LAGC who underwent radical resection plus adjuvant chemotherapy or chemoradiotherapy from July 2003 to December 2014 were included. Validation cohort were selected from SEER database between 2004 and 2014. Kaplan-Meier and Cox proportional hazardous models were used to evaluate the overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Propensity score matching (PSM) was used to adjust for potential baseline confounding. Results: A total of 350 patients were included and divided into D1 dissection plus chemotherapy group (D1CT, n = 74), D1 dissection plus adjuvant chemoradiotherapy group (D1CRT, n = 69), D2 dissection plus adjuvant chemotherapy group (D2CT, n = 134), and D2 dissection plus adjuvant chemoradiotherapy group (D2CRT, n = 73). PSM identified 50 patients in each group. After PSM, better DFS (P for D2CRT vs. D1CT, D1CRT, and D2CT was 0.001, 0.006, and 0.001, respectively) and OS (P for D2CRT vs. D1CT, D1CRT, and D2CT was 0.001, 0.011, and 0.022, respectively) were found for the D2CRT group (mean, OS = 110.7months, DFS = 95.2 months) than the other groups. Similar findings were further validated in the Surveillance, Epidemiology, and End Results database (SEER) cohort. In addition, patients in the D1CRT group achieved similar survival outcomes to those in the D2CT group (mean OS, 72.8 vs. 59.1 months, P = 0.86; mean DFS, 54.4 vs. 34.1 months, P = 0.460). Conclusions: The results of the study indicated the better role for D2CRT in treating the LAGC, meanwhile, the patients treated with D1CRT might achieve similar survival as that of D2CT patients.

Keywords: Adjuvant therapy; D1 dissection; D2 dissection; Gastric cancer; Propensity score matching; SEER.